7492results about "Peptides" patented technology

This disclosure provides cyclic peptide compounds of formula (A) or formula (II) as inhibitors of Ras kinase, and compositions and use of the same in treating diseases associated with Ras kinase.

Disclosed are a hexapeptide compound and a composition and use thereof, relating to the technical field of polypeptides, the peptide or a salt thereof having a structure as shown in formula (I): R1-Val-Leu-Gln-Trp-Val-Lys-R2 (I). In particular, the invention relates to the peptide or the salt thereof, or a composition of the peptide and the salt thereof, and application of the peptide and the salt in preparation of a composition for nursing or treating skin or mucous membranes.

The invention relates to the field of preparation and application of biological peptides, in particular to a hippocampal swelling peptide and application thereof in preparation of functional products for repairing male reproductive system injury. A green controllable enzymolysis technology is utilized to obtain protein polypeptide with nutritional, health-care and medicinal values, an active peptide sequence with high biological activity is obtained through further research on the basis, high-purity active peptide is obtained through a chemical synthesis mode, and the biological activity of the peptide is verified through mouse spermatogonium.

The invention belongs to the technical field of biochemical engineering, and provides a method for increasing L-carnosine yield of escherichia coli by increasing PRPP supply, and the yield and yield of L-carnosine are remarkably increased by up-regulating expression of a prs gene, increasing PRPP content in cells and promoting synthesis of L-histidine. Experiments show that the yield of the L-carnosine in different recombinant strains is increased by 55.56%-140%, and L-histidine and beta-alanine do not need to be added in the production process.

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention provides an antibacterial peptide cAMP048 sourced from microorganisms in a deep sea environment and application of the antibacterial peptide cAMP048, and belongs to the technical field of peptide inhibitors. The antibacterial peptide cAMP048 has an amino acid sequence as shown in SEQ ID NO: 1 (Sequence Identity Number 1). The antibacterial peptide can inhibit the growth of acinetobacter baumannii at 64 mu M, inhibit the growth of multi-drug-resistant acinetobacter baumannii and multi-drug-resistant enterococcus faecium at 128 mu M and inhibit the growth of escherichia coli, staphylococcus aureus and multi-drug-resistant klebsiella pneumoniae at 256 mu M. The antibacterial peptide can be used for preparing products with antibacterial and / or bactericidal performance, and can be applied to preparation of antibacterial and / or bactericidal products. Such as food, skin care products or medical supplies.

The invention relates to the technical field of genetic engineering, and particularly discloses a genetic engineering bacterium for producing melanin as well as a construction method and application of the genetic engineering bacterium. According to the application, the yield of the melanin can be effectively increased by modifying a metabolic pathway of the genetically engineered bacterium, and the yield of the melanin reaches 6.2 g / L and 18.5 g / L respectively through shake-flask culture and 5L fermentation tank culture. Compared with the prior art, the yield of melanin produced by the genetically engineered bacterium is improved by 30% at the shake flask fermentation level, the fermentation yield of a fermentation tank is improved by 4.3 times, in addition, expensive tyrosine is changed into glucose as a fermentation precursor substance, the production cost is greatly reduced, and an efficient and feasible solution is provided for large-scale production of melanin.

The invention discloses a method for improving beef quality, an action mechanism and an experimental method, in a cattle body, vitamin A can activate the expression of EBF2 through an active metabolite RA of the vitamin A, and the EBF2 can inhibit the transcription process of CYP26B1 in a targeted manner to maintain the activity of a retinol signal channel, so that PPAR gamma and downstream lipid metabolism related genes thereof are activated, and the activity of the retinol signal channel is improved. Fatty acid transport and lipid accumulation in fat cells in the cattle muscle are promoted, fat deposition in the cattle muscle is promoted, and the beef quality is improved. By constructing the molecular network for regulating and controlling the formation of the fat in the cattle muscle, a complex regulation and control mechanism for controlling the fat deposition in the cattle muscle can be understood more deeply, a method for improving the beef quality based on regulating and controlling the vitamin A mediated key factor EBF2 is provided, and a new way is provided for improving the beef quality in a targeted manner.

The invention belongs to the technical field of biological medicines, and particularly relates to a composition for treating male erectile dysfunction and application thereof. The oyster polypeptide is prepared by enzymolysis of oyster protein, can effectively promote proliferation of testicular interstitial cells, enhance and improve sexual desire and improve sexual behavior, has certain clinical application value, has the advantages of simple preparation, easy absorption and the like, and is easy to popularize and apply.

Disclosed are a pentapeptide compound and a composition and use thereof, relating to the technical field of polypeptides, the peptide or a salt thereof having a structure as shown in formula (I): R1-Lys-Lys-Leu-Ala-R2 (I). The invention also relates to a cyclic peptide, and the structure of the cyclic peptide is Cyclo-[Lys-Lys-Lys-Leu-Ala]. The compound disclosed by the invention has the effects of controlling oil, repairing, resisting oxidation and the like, and can be used for nursing skin or mucosa.

The invention discloses a photocatalytic preparation method of a deuterated acetamide compound, and belongs to the technical field of synthesis of deuterated acetamide compounds. According to the technical scheme, the method is characterized in that a dichloroacetamide compound is used as a raw material, D2O is used as a deuterium source, and the dideuterated acetamide compound is synthesized through reaction under the room-temperature nitrogen illumination condition; according to the method, dichloroacetamide compounds are taken as raw materials, D2O is taken as a deuterium source, deuterated dichloroacetamide compounds are synthesized through room-temperature reaction, and monodeuterated or trideuterated acetamide compounds are respectively obtained through photocatalytic reaction according to different solvents (H2O or D2O) added into a system. The preparation method provided by the invention has the advantages of simple and safe operation, mild reaction conditions, no transition metal participation, cheap and easily available deuterium source, high deuteration rate, controllable number and the like.

The invention belongs to the field of molecular biology, and particularly relates to a transgenic soybean event LP207-1 and a detection method thereof. The invention provides a nucleic acid sequence for detecting a transgenic soybean event LP207-1, the nucleic acid sequence is selected from one or more of sequences SEQ ID NO: 1-7 or complementary sequences thereof, and the nucleic acid sequence is derived from a plant, a seed or a cell of the transgenic soybean event LP207-1. A representative sample of a seed of the transgenic soybean event LP207-1 is preserved in the China Center for Type Culture Collection on May 23, 2025, and the preservation number is CCTCC NO: P202516. The transgenic soybean event LP207-1 has good resistance to lepidoptera pests and can tolerate agricultural herbicides containing glyphosate and glufosinate-ammonium, economic loss caused by the lepidoptera pests can be avoided, and the yield is not reduced; and the breeding efficiency is enhanced, and the molecular marker can be used for tracking a breeding population and transgenic insertion fragments in offspring of the breeding population. The detection method provided by the invention can quickly, accurately and stably identify the existence of the plant material derived from the transgenic soybean event LP207-1.

The invention discloses a cyclic hexapeptide for skin care and a composition and application thereof, and relates to the technical field of polypeptides, and the cyclic peptide has the following structure: Cyclo-[Arg-Arg-Gln-D-Met-Glu-Glu]. Specifically, the invention relates to the cyclic peptide or the salt thereof, or a composition of the cyclic peptide and the salt thereof, and application of the cyclic peptide and the salt in preparation of a composition for nursing or treating skin or mucosa.

The invention relates to antarctic krill peptide with umami and an antarctic krill peptide mixture as well as a preparation method and application thereof. Specifically, the amino acid sequence of the euphausia superba peptide is shown as any one of SEQ ID NO: 1-5. The euphausia superba peptide mixture with delicate flavor is obtained by carrying out enzyme digestion treatment on an euphausia superba peptide solution by using incision enzyme, excision enzyme and freshness enhancing enzyme and harvesting supernate. Molecular docking simulation shows that the euphausia superba peptide disclosed by the invention can be combined with a delicate flavor receptor T1R1 / T1R3. The Antarctic krill peptide and the Antarctic krill peptide mixture can be used for development of umami seasonings, and a new idea is provided for development of marine seasonings.

The invention provides an enhancer RNA (Ribonucleic Acid) molecule MZGAe1 and application thereof, and relates to the technical field of biology. The invention provides an enhancer RNA (Ribonucleic Acid) molecule MZGAe1. The nucleotide sequence of the enhancer RNA molecule MZGAe1 is as shown in SEQ ID NO: 1; meanwhile, the invention further provides a specific sgRNA sequence for activating the molecule in a targeted manner and a recombinant vector of the specific sgRNA sequence. Expression of endogenous MZGAe1 of cells is specifically activated by adopting a CRISPR activation technology, and conversion of mouse embryonic stem cells to bicellular-like cells can be efficiently promoted. By providing a brand-new endogenous targeted MZGAe1 accurate activation tool, the efficient transformation of wild mouse embryonic stem cells to bicellular cells can be realized only under the condition of endogenous activation of single enhancer RNA molecule MZGAe1, the proportion is at least increased by 5%, the expression of a totipotent marker gene ZSCAN4 is activated, and the expression of the totipotent marker gene ZSCAN4 is promoted. And an efficient and specific brand-new research tool and scheme are provided for researching zygote genome activation, embryonic development early events and cell reprogramming.

The invention discloses an application of an HERP gene knockout mouse model in obesity and metabolic disorder diseases. The invention finds that compared with a wild type high-fat group, HERP gene knockout can cause phenotypes such as early obesity, more serious obesity degree, increase of fat weight ratio, aggravation of adipose tissue inflammation, dyslipidemia and glucose metabolism disorder of mice during high-fat feeding. And the HERP gene is knocked out, so that the adipocyte differentiation is increased. The HERP gene knockout mouse is more sensitive to nutrition, obesity can occur more quickly during high-fat feeding, symptoms such as fat amplification, fat inflammation and glucose and lipid metabolism disorder are more serious, and the HERP gene knockout mouse can be used for molecular mechanism research and drug screening of obesity, fat tissue and glucose and lipid metabolism disorder. It is further found that cilostazol can significantly relieve mouse obesity and lipid metabolism disorder caused by HERP gene defects, but has no obvious weight losing effect on normal genotype mice, and a new strategy is provided for precise treatment.

The present application relates to the field of biomedicine, and in particular to a tumor antigen peptide and a use thereof. Provided is a tumor antigen peptide, comprising a peptide segment having an amino acid sequence as shown in SEQ ID NO: 1. The provided tumor antigen peptide can be presented by the HLA subtype (HLA-A*11:01) having a high proportion of Chinese population. Additionally, by means of in vitro stimulation, the tumor antigen peptide is verified to effectively stimulate specific T cells, and a specific TCR element is successfully obtained. The present application lays a direct foundation for further developing TCR-T therapy targeting human TP53 R248Q and immunotherapy such as therapeutic vaccines.

Optimization of the formula of a culture medium for industrially producing a Bacillus velezensis TCS001 fermentation broth and culture process conditions therefor. By using the culture medium and the culture process conditions, not only can the fermentation production cost be reduced, but also the effective viable bacterium count and the spore count in the Bacillus velezensis TCS001 fermentation broth can be improved, so that the fermentation broth can be used for industrial production and market promotion and application. Provided is a lipopeptide-compound-containing mixture separated from a Bacillus velezensis TCS001 fermentation broth. By further optimizing the formula of the culture medium for the Bacillus velezensis TCS001 fermentation broth and the culture fermentation process conditions, the output and yield of lipopeptide compounds in the fermentation broth are successfully improved, providing an efficient and cost-effective solution for the control of plant diseases.

The invention discloses a full D-type antibacterial peptide with high enzymolysis stability and broad-spectrum antibacterial activity and application thereof. The antibacterial peptide is obtained by sequentially and repeatedly arranging D-type tryptophan, D-type arginine and D-type lysine for four times and carrying out C-terminal amidation; the amino acid sequence of the gene is (D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-NH2, and is marked as DWRK-12. The antibacterial peptide shows broad-spectrum antibacterial activity and excellent stability, can effectively resist clinically separated multidrug resistant strains, and keeps high cell selectivity at the same time. Due to the characteristics, the antibacterial peptide has important application value in the aspect of developing novel antibacterial drugs, especially in the field of treatment of infection of multiple drug-resistant bacteria.

The invention provides a UTR (Untranslated Region) sequence for improving mRNA (Messenger Ribonucleic Acid) stability and translation efficiency and application of the UTR sequence, and particularly provides an mRNA molecule which comprises a coding region for coding polypeptide or protein and a fragment thereof, a 5 'UTR sequence positioned at the upstream of the coding region and / or a 3' UTR sequence positioned at the downstream of the coding region, the 5 'UTR sequence is a nucleotide sequence as shown in SEQ ID NO: 1, and the 3' UTR sequence is a nucleotide sequence as shown in SEQ ID NO: 2; and / or, the 5 'UTR sequence is a nucleotide sequence as shown in SEQ ID NO: 3, and the 3' UTR sequence is a nucleotide sequence as shown in SEQ ID NO: 4. According to the present invention, the mRNA stability and the translation efficiency are improved through the new and optimized UTR sequence, and the UTR sequence can be used as the element for enhancing the RNA expression efficiency in the nucleic acid treatment drug or the mRNA vaccine so as to provide more and better choices for the mRNA therapy.

The invention discloses a camel blood polypeptide and application thereof in preparation of an alpha-glucosidase inhibitor, a series of polypeptide products are separated from camel blood, and it is found that the camel blood polypeptide with the amino acid sequence being YFKI, DPPTMEL, DKPFGPDL or SEPSGTAFG has the remarkable alpha-glucosidase inhibitory activity; the compound can be applied to preparation of drugs for treating diseases caused by abnormal activity of alpha-glucosidase.

The invention discloses a method for regulating the transport activity of a strain to 1-aminocyclopropane-1-carboxylic acid, and relates to the technical field of bioengineering. The method for regulating and controlling the transport activity of the strain to 1-aminocyclopropane-1-carboxylic acid and / or methionine analogues and the tolerance of the strain to the 1-aminocyclopropane-1-carboxylic acid and / or methionine analogues, disclosed by the invention, comprises the step of transferring a LeuE gene into escherichia coli to obtain an escherichia coli recombinant strain with corresponding functions. The invention discloses the application of the LeuE protein and the LeuE gene in regulating and controlling the transport activity of escherichia coli to the 1-aminocyclopropane-1-carboxylic acid and / or methionine analogue and the tolerance of escherichia coli to the 1-aminocyclopropane-1-carboxylic acid and / or methionine analogue for the first time. The invention discloses that LeuE is an optimal candidate gene for constructing ACC synthetic bacteria for the first time, and the substrate specific transport of the LeuE meets the aim of enhancing the ACC tolerance of cells without influencing precursor supply.

The invention discloses a cyclic nonapeptide with repairing and anti-oxidation effects and application of the cyclic nonapeptide, the amino acid sequence of the cyclic nonapeptide is cyclic (arginine-glycine-aspartic acid-serine-arginine-lysine-valine-lysine-serine), the prepared cyclic nonapeptide has the repairing and anti-oxidation effects, and the cyclic nonapeptide has the repairing and anti-oxidation effects. The composition can be applied to preparation of cosmetics with repairing and / or anti-oxidation effects.

The invention provides a fibroblast activating protein targeting compound, a nuclide marker of the fibroblast activating protein targeting compound, a pharmaceutical composition containing the fibroblast activating protein targeting compound and application of the fibroblast activating protein targeting compound and the nuclide marker, and relates to the technical field of nuclide drugs. The fibroblast activating protein targeting compound comprises a compound shown as a formula I, and has remarkably enhanced tumor uptake and retention time. The invention also relates to a pharmaceutical composition and a kit containing the targeting compound, and application of the compound in diagnosis or treatment of fibroblast activating protein overexpression diseases. # imgabs0 #

Provided herein are novel cyclic peptides, their synthetic process, compositions, properties including stability and pharmacokinetic profiles, and applications for treating solid tumor cancers.

The invention relates to the technical field of bioengineering, in particular to streptomyces noursei capable of producing multimycotin B and application of the streptomyces noursei. According to the invention, gene editing is carried out on the nysL gene and the nysGtf gene or a combination thereof in the streptomyces nosella, so that the yield of the polymycotin B in the streptomyces nosella is remarkably improved. According to the streptomyces noursei for producing the multi-fungal element B, the multi-fungal element B can be efficiently synthesized and accumulated by utilizing low-cost raw materials, the yield of the multi-fungal element B is remarkably increased, and the streptomyces noursei can be used for producing the multi-fungal element B or increasing the content ratio of the multi-fungal element B in prepared nystatin. According to the streptomyces noursei and the method for producing the multi-fungal element B by using the streptomyces noursei, provided by the invention, a strain resource and an effective method are provided for producing the multi-fungal element B and producing nysfungin with a high multi-fungal element B content ratio, and the streptomyces noursei has a relatively good application prospect.

Provided are a ligand-drug conjugate represented by general formula Pc-(L-D)n or a pharmaceutically acceptable salt thereof, and further provided is a linker for conjugation represented by formula (L). The linker can efficiently and highly selectively perform chemical conjugation with a thiol group on cysteine, and the antibody-drug conjugate formed has good stability.

The invention discloses a polypeptide drug for resisting gram-negative bacteria and application, and belongs to the technical field of biological medicine. The MIC of the antibacterial peptide obtained through screening on escherichia coli, salmonella typhimurium, pseudomonas aeruginosa, klebsiella pneumoniae, shigella sonnei and stenotrophomonas maltophilia is 16 [mu] g / mL, 2 [mu] g / mL, 16 [mu] g / mL, 4 [mu] g / mL, 2 [mu] g / mL and 4 [mu] g / mL respectively, and the antibacterial peptide has broad-spectrum antibacterial performance. The hemolytic activity and toxicity of the compound are lower than therapeutic concentration threshold values, and the compound can be used for preparing drugs or medical products for treating multi-drug-resistant bacterium infection.

The present invention relates to a method for constructing an eight-gene-edited xenogeneic organ transplantation donor pig, belonging to the field of animal biotechnology. In the wild-type porcine fetal fibroblast cell line, the GGTA1, β4GalNT2, and CMAH genes are knocked out by using the CRISPR / Cas9 gene editing technology, and the humanized genes of hCD39, hCD46, hCD55, hCD59, and hTBM are transfected. Combining with somatic cell cloning technology, GTKO / β4GalNT2KO / CMAHKO / hCD39 / hCD46 / hCD55 / hCD59 / hTBM eight-gene-edited cloned pigs are constructed. Further, through genotype, mRNA, protein expression identification and functional analysis, eight-gene-edited xenogeneic organ transplantation donor pigs are obtained. The present invention solves the technical problems of high production difficulty, low efficiency, and low survival rate of donor pigs for multi-gene-edited xenogeneic organ transplantation, and maximally solves the common problems of immune rejection reaction and complement dysregulation faced during xenogeneic organ transplantation, laying a foundation for more targeted development of donor pigs suitable for different tissue and organ xenotransplantation, and having important value for promoting the clinical transformation of xenogeneic organ transplantation.